Roivant Sciences第三季度调整后每股亏损$(0.20)胜出预期$(0.28),销售额900.2万美元未达预期1599.9万美元

财报速递2025-02-10
Roivant Sciences (NASDAQ:ROIV) 报告季度每股亏损$(0.20),优于分析师一致预期的$(0.28),相差28.57%。这一结果较去年同期的每股亏损$(0.21)增长了4.76%。公司报告季度销售额为900.2万美元,未达到分析师一致预期的1599.9万美元,相差43.60%。这较去年同期的销售额1556万美元下降了42.05%。

以上内容来自Benzinga Earnings专栏,原文如下:

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 4.76 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $9.02 million which missed the analyst consensus estimate of $15.99 million by 43.60 percent. This is a 42.05 percent decrease over sales of $15.56 million the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法